Ra Capital Management, L.P. C4 Therapeutics, Inc. Transaction History
Ra Capital Management, L.P.
- $6.64 Billion
- Q2 2024
A detailed history of Ra Capital Management, L.P. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 4,878,000 shares of CCCC stock, worth $31.4 Million. This represents 0.34% of its overall portfolio holdings.
Number of Shares
4,878,000Holding current value
$31.4 Million% of portfolio
0.34%Shares
4 transactions
Others Institutions Holding CCCC
# of Institutions
119Shares Held
53.8MCall Options Held
331KPut Options Held
145K-
Wasatch Advisors Inc Salt Lake City, UT4.85MShares$31.2 Million0.12% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$29.3 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT4.05MShares$26.1 Million1.9% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.56MShares$22.9 Million0.0% of portfolio
-
Commodore Capital LP New York, NY3.41MShares$21.9 Million1.41% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $315M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...